UY30693A1 - Usos de variantes de un activador de plasminogeno de tejidos - Google Patents

Usos de variantes de un activador de plasminogeno de tejidos

Info

Publication number
UY30693A1
UY30693A1 UY30693A UY30693A UY30693A1 UY 30693 A1 UY30693 A1 UY 30693A1 UY 30693 A UY30693 A UY 30693A UY 30693 A UY30693 A UY 30693A UY 30693 A1 UY30693 A1 UY 30693A1
Authority
UY
Uruguay
Prior art keywords
variants
tenecteplase
plasminogen activator
tissue plasminogen
catheter
Prior art date
Application number
UY30693A
Other languages
English (en)
Spanish (es)
Inventor
Martha E Blaney
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of UY30693A1 publication Critical patent/UY30693A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/285—Catheters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M2025/0019—Cleaning catheters or the like, e.g. for reuse of the device, for avoiding replacement

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY30693A 2006-11-07 2007-11-07 Usos de variantes de un activador de plasminogeno de tejidos UY30693A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86475806P 2006-11-07 2006-11-07
US98348907P 2007-10-29 2007-10-29

Publications (1)

Publication Number Publication Date
UY30693A1 true UY30693A1 (es) 2008-05-02

Family

ID=39362326

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30693A UY30693A1 (es) 2006-11-07 2007-11-07 Usos de variantes de un activador de plasminogeno de tejidos

Country Status (10)

Country Link
US (1) US8916148B2 (https=)
EP (1) EP2086571A2 (https=)
JP (1) JP5871449B2 (https=)
AR (1) AR063603A1 (https=)
CA (1) CA2668347C (https=)
CL (1) CL2007003211A1 (https=)
PE (2) PE20081488A1 (https=)
TW (1) TW200826981A (https=)
UY (1) UY30693A1 (https=)
WO (1) WO2008070353A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533029A (en) 2001-11-26 2006-05-26 Genentech Inc Composition useful for removal of fibrin-bound blood clot from a catheter comprises water, a plasminogen activator and an alcohol
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
JP6375112B2 (ja) 2010-12-23 2018-08-15 ジェノヴァ バイオファーマシューティカルズ リミテッド テネクテプラーゼの医薬組成物
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
PL3209767T3 (pl) * 2014-10-21 2021-01-11 Gennova Biopharmaceuticals Ltd. Nowy sposób oczyszczania do izolacji i komercyjnej produkcji zrekombinowanego tnk-tpa (tenekteplazy)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484A7 (fi) 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) 1988-09-07 1988-10-05 Smith & Nephew Medical articles
NZ230808A (en) 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
US5399158A (en) 1990-05-31 1995-03-21 The United States Of America As Represented By The Secretary Of The Army Method of lysing thrombi
US5363754A (en) 1991-09-03 1994-11-15 Grainco Queensland Co-Operative Association Limited Apparatus for preparing animal feedstuff from cotton seed
ATE155816T1 (de) 1992-06-03 1997-08-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DK0730590T3 (da) 1993-11-24 2001-03-19 Du Pont Pharm Co Isoxazolin og isozazol fibrinogenreceptorantagonister
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5556380A (en) 1995-04-05 1996-09-17 Duke University Method for removing fibrin sheaths from catheters
US5772640A (en) 1996-01-05 1998-06-30 The Trustees Of Columbia University Of The City Of New York Triclosan-containing medical devices
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
AU5526098A (en) 1996-12-23 1998-07-17 Biochem Pharma Inc. Bicyclic thrombin inhibitors
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
US5981826A (en) 1997-05-05 1999-11-09 Georgia Tech Research Corporation Poly(vinyl alcohol) cryogel
JPH10328293A (ja) 1997-06-04 1998-12-15 Unitika Ltd 医療用具及びその製造方法
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) 1998-09-25 2001-01-16 Becton, Dickinson And Company Catheter flush solution and method for its use
EP1189663A2 (en) 1999-03-11 2002-03-27 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
CN1346292A (zh) 1999-03-11 2002-04-24 杜邦药品公司 凝血因子Xa抑制剂与阿司匹林、组织纤溶酶原激活物(TPA)、GPⅡb/Ⅲa拮抗剂、低分子量肝素或肝素联合用于治疗血栓形成
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
EP1060747A3 (en) 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) 1999-07-23 2003-07-15 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) * 2000-01-18 2002-02-26 Biolink Corporation Biocidal locks
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
EP1284780B1 (en) 2000-05-10 2008-05-07 Ash Access Technology, Inc. A catheter lock solution including a photo-oxidant
AU2001285245A1 (en) 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US20050215978A1 (en) * 2001-05-25 2005-09-29 Ash Stephen R Method of enhancing catheter patency using a citrate salt catheter lock solution
NZ533029A (en) * 2001-11-26 2006-05-26 Genentech Inc Composition useful for removal of fibrin-bound blood clot from a catheter comprises water, a plasminogen activator and an alcohol
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
ATE354380T1 (de) 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Also Published As

Publication number Publication date
CA2668347C (en) 2017-06-20
WO2008070353A2 (en) 2008-06-12
AR063603A1 (es) 2009-02-04
EP2086571A2 (en) 2009-08-12
TW200826981A (en) 2008-07-01
CL2007003211A1 (es) 2008-05-30
PE20081488A1 (es) 2008-10-30
JP5871449B2 (ja) 2016-03-01
US8916148B2 (en) 2014-12-23
JP2010509229A (ja) 2010-03-25
WO2008070353A3 (en) 2008-08-28
US20120270299A1 (en) 2012-10-25
PE20120639A1 (es) 2012-05-26
CA2668347A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
UY30693A1 (es) Usos de variantes de un activador de plasminogeno de tejidos
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
TR201818927T4 (tr) Kataterlerde İyileştirme
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
DOP2003000585A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
UY31418A1 (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
CL2008002466A1 (es) Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado.
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
ECSP077843A (es) Tratamiento o prevención del prurito

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170731